Published in final edited form as:

Antiviral Res. 2007 November ; 76(2): 124–129.

Efficacy of *N*-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus

Donald F. Smee^a, Brett L. Hurst^a, Min-Hui Wong^a, Robert I. Glazer^b, Aquilur Rahman^b, and Robert W. Sidwell^a

^a*Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah 84322-5600, USA*

^b*Department of Oncology, Georgetown University School of Medicine, Washington, D.C. 20007, USA*

Abstract

N-methanocarbathymidine [(*N*)-MCT] is a newly identified inhibitor of orthopoxvirus replication in cell culture and in mice. Limited published animal studies indicated the compound is effective by intraperitoneal (i.p.) route at 10-100 mg/kg/day. More extensive studies using different treatment regimens in intranasally-infected mice were conducted in order to further explore the potential of this compound compared to cidofovir in treating vaccinia virus infections. (*N*)-MCT was given twice a day for 7 days, whereas cidofovir was administered once a day for 2 days, each starting 24 h after virus exposure for most experiments. (*N*)-MCT was not toxic up to 1000 mg/kg/day by the i.p. treatment route. Oral and i.p. treatment regimens with (*N*)-MCT were directly compared during a vaccinia virus (IHD strain) infection, indicating that the nucleoside has good oral bioavailability in mice. Treatments by i.p. route with (*N*)-MCT (100 mg/kg/day) reduced lung, nasal, and brain virus titers during an IHD virus infection, but not nearly to the same extent as i.p. cidofovir (100 mg/kg/day). Treatment with both compounds decreased liver, spleen, and kidney virus titers, as well as reduced lung consolidation scores and lung weights. Onset of treatment could be delayed by 2 days with (*N*)-MCT and by 3 days with cidofovir, providing significant survival benefit during the IHD virus infection. Against a vaccinia virus (WR strain) infection in mice, i.p. (*N*)-MCT treatment prevented death at 500 mg/kg/day, which was comparable in activity to i.p. cidofovir (100 mg/kg/day). Significant reductions in tissue virus titers occurred with both treatment regimens. (*N*)-MCT could be further pursued for its potential to treat orthopoxvirus infections in humans.

Keywords

antiviral; orthopoxvirus; vaccinia virus; (*N*)-MCT; cidofovir; thymidine

1. Introduction

Antiviral treatments are being sought against infections caused by orthopoxviruses and parapoxviruses, including complications due to smallpox vaccination (Bray, 2003), molluscum contagiosum (Baxter and Highet, 2004; Arican, 2006; Brown et al., 2006), orf viruses (De Clercq, 2002; McCabe et al., 2003; Erbağci et al., 2005), or resulting from acts of bioterrorism (Baker et al., 2003; Jahrling et al., 2005). In certain infections antiviral treatment has been

Corresponding author: Tel: +1 435 797 2897; fax: +1 435 797 3959, *E-mail address:* dsmee@cc.usu.edu (D. F. Smee).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

shown to be superior to vaccination (Stittelaar et al., 2006). Cidofovir, a nucleotide analog, and cidofovir prodrugs are leading candidates for treatment of poxvirus infections, and have been investigated in various animal models (Bray et al., 2000; De Clercq, 2002; Smee and Sidwell, 2003; De Clercq and Neyts, 2004; Quenelle et al., 2003, 2004; Smee et al., 2004). Cidofovir acts by inhibiting viral DNA polymerase activity (Magee et al., 2005). Due to toxicity and the lack of oral bioavailability of cidofovir (Wachsman et al., 1996), it would be desirable to identify other inhibitory substances that might be useful in treating poxvirus infections. Recently a low molecular weight compound, 4-trifluoromethyl-*N*-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[*f*]isoindol-2(1H)-yl)-benzamide (ST-246), was reported to possess potent anti-poxvirus activity in cell culture and in mice (Yang et al., 2005). ST-246 is not a nucleoside/nucleotide analog, and inhibits virus replication by inhibiting a step involved in virus particle maturation to the extracellular form. Thus, it represents a potential drug candidate with a mode of action different from that of cidofovir.

We have evaluated a number of potential anti-poxvirus agents exhibiting antiviral activity in vitro, most of which are 2'-deoxynucleoside/nucleotide analogs and generally target the viral DNA polymerase. One such compound, *N*-methanocarbathymidine [(*N*)-MCT, also referred to as (north)-methanocarbathymidine (Marquez et al., 1996; Zalah et al., 2002), *N*-methanocarbathymine or (north)-methanocarbathymine (Russ et al., 2003)], was shown to inhibit cowpox and vaccinia viruses in cell culture and infected mice (Prichard et al., 2006; Smee et al., 2007). It also inhibits herpes viruses (Marquez et al., 1996; Zalah et al., 2002; Russ et al., 2003; Huleihel et al., 2005) by first undergoing phosphorylation in infected cells (Zalah et al., 2002; Marquez et al., 2004; Schelling et al., 2004) and inhibiting the viral DNA polymerase at the nucleoside triphosphate level (Marquez et al., 2004). (*N*)-MCT is a carbocyclic analog of thymidine. Its spectrum of anti-poxvirus activity is similar to that of carbocyclic thymidine (Smee et al., 2007).

We found (*N*)-MCT to be non-toxic to mice at high doses, and thus is an interesting candidate for the treatment of poxvirus infections. Previously (*N*)-MCT was investigated in mice at doses of 10-100 mg/kg/day, principally by intraperitoneal treatment route (Prichard et al., 2006; Smee et al., 2007). At these doses, vaccinia (WR strain) virus was less affected by antiviral treatment than were vaccinia (IHD strain) and cowpox viruses. The objectives of the present research were to determine the oral efficacy of (*N*)-MCT, and to study different treatment regimens against vaccinia virus infections in mice. Particularly, we were interested in defining regimens that may be more effective in preventing death, reducing virus burden, and establishing how late after infection treatments could be initiated and still be effective.

2. Materials and methods

2.1. Viruses and test compounds

Vaccinia viruses (IHD and WR strains) were purchased from the American Type Culture Collection, Manassas, VA. The viruses were propagated in African green monkey kidney (MA-104) cells (BioWhittaker, Walkersville, MD) for use in these studies. (*N*)-MCT was provided to us through the NIAID antiviral testing program. Cidofovir was obtained from Mick Hitchcock (Gilead Sciences, Foster City, CA). Sterile water was used to dissolve (*N*)-MCT up to 100 mg/kg/day for oral dosing. Studies with higher doses required formulating the compound in water containing 20% (2-hydroxypropyl)— β -cyclodextrin (HPCD, Sigma, St. Louis, MO). Sterile saline containing 20% HPCD was used for high-dose intraperitoneal (i.p.) treatments. The placebo controls received the same HPCD formulations. Cidofovir in sterile saline was given by i.p. route.

2.2. Animal Experiment Design

Female BALB/c mice (13-15 g, from Charles River Laboratories, Wilmington, MA) were anesthetized with Ketamine (100 mg/kg) by i.p. injection. They were infected intranasally with approximately 1×10^5 plaque forming units of vaccinia virus per mouse in a 50- μ l inoculum volume. The animals were treated orally by gavage or i.p. with (N)-MCT, or i.p. with cidofovir in a 100 μ l volume. Cidofovir is not effective orally due to very low oral bioavailability (Wachsmann et al., 1996). Treatments with (N)-MCT were given twice a day (12 h apart) for 7 days whereas cidofovir (100 mg/kg/day) was administered once a day for 2 days. These regimens have previously been shown to be effective for treating poxvirus-infected mice (Smee et al., 2007). Treatments usually started 24 h after virus challenge, or as indicated in one of the tables. The placebo was given in parallel with the (N)-MCT group. Animals were observed 21 days for death.

Virus titer determinations were made from tissues taken from groups of 5 infected mice held for this purpose during the infection. Homogenization of soft tissues was done in 1 ml of cell culture medium (MEM, 0.18% sodium bicarbonate, 50 μ g/ml gentamicin) using a stomacher. Snouts and accompanying nasal tissues were ground in 1 ml of medium using sterilized mortars and pestles. Samples were serially diluted in 10-fold increments and plaque titrated in rhesus monkey kidney LLC-MK₂ cells (obtained from the American Type Culture Collection, Manassas, VA). Plaques were stained at three days with 0.2% crystal violet in 10% buffered formalin, then were counted with the aid of a light box. Plaque numbers were converted to plaque forming units (PFU) per gram of lung tissue. Because the severe infections also induced pneumonitis, we were able to report lung consolidation scores (graded from 0 to 4) and lung weights as part of the experiment.

2.3 Statistical Evaluation

The two-tailed Fisher exact test was used to evaluate survivor number increases. The two-tailed Mann-Whitney U-test was used to analyze differences in the mean day of death, lung infection parameters (consolidation score and weight), and tissue virus titers. All statistical comparisons were made between drug-treated groups and the placebo control.

3. Results

3.1. Toxicity of (N)-MCT in uninfected mice

(N)-MCT was administered i.p. twice a day for 7 days at doses of 100, 250, 500, 750 and 1000 mg/kg/day. Animal weights were recorded daily for 21 days. Mice treated with all doses of (N)-MCT gained weight in parallel with placebo-treated mice, indicating a lack of toxicity of the compound up to 1000 mg/kg/day. Doses as high as 500 mg/kg/day were selected for antiviral experiments.

3.2. Oral activity of (N)-MCT against vaccinia virus (IHD strain) infections in mice

Previously (N)-MCT was found to be highly effective when given by i.p. route against vaccinia virus (IHD strain) infections (Prichard et al., 2006; Smee et al., 2007), with complete protection at 10, 30, and 100 mg/kg/day reported in the latter study. To extend these observations, treatments were performed against the IHD infection by directly comparing i.p. and oral routes of administration evaluated at the same time (Table 1). Oral and i.p. doses at 100 and 30 mg/kg/day gave nearly the same degree of protection (Experiment 1). At 10 mg/kg/day, the oral and i.p. treatments gave 70% and 30% protection, respectively. These results at 10 mg/kg/day were not statistically significantly different from each other, however. There was a considerable delay in death in the 10 mg/kg/day i.p. group. To confirm these findings, a repeat experiment was conducted, and the results are presented in Table 1, Experiment 2. In this study (N)-MCT

was not as protective as in the first test. Both oral and i.p. doses were protective at the 100 mg/kg/day dose, but oral treatment was more active than i.p. administration at the 30 mg/kg/day dose. Neither treatment was significantly effective at the 10 and 3 mg/kg/day doses. In both experiments the results indicate that (N)-MCT is effective by the oral route in mice.

A follow-up experiment was conducted with (N)-MCT at higher doses compared to cidofovir at 100 mg/kg/day to assess effects on mortality and lung infection parameters (Table 2). Survival benefit was afforded by oral (N)-MCT treatments of 100, 250, and 500 mg/kg/day, and by i.p. cidofovir at 100 mg/kg/day. The two higher doses of (N)-MCT were superior to the 100 mg/kg/day dose in reducing lung virus titers, but virus titer reduction was not as great as that resulting from cidofovir treatment. Both compounds were effective in significantly reducing lung consolidation scores and lung weights on day 5 of the infection.

3.3. Effects of treatment on pathogenesis of a vaccinia virus (IHD strain) infection

(N)-MCT did not have a large impact in reducing lung virus titers by either oral treatment or by the i.p. route (Smee et al., 2007) when compared to cidofovir, as determined on day 5 of the infections. The pathogenesis of the vaccinia virus (IHD strain) infection was studied over several days using an i.p. dose of 100 mg/kg/day. Lung consolidation score and lung weight parameters of the infection are shown in Figure 1. Lung scores and weights were elevated in the placebo group on days 5 and 7 of the infection, being highest just prior to death of the animals. (N)-MCT and cidofovir treatments resulted in significant decreases in these parameters relative to the placebo group. The effects of cidofovir appeared to be slightly better than those of (N)-MCT in reducing these lung infection parameters, although the differences in the results were not statistically significant.

The effects of antiviral treatment on virus titers in six different tissues during the IHD virus infection are presented in Figure 2. On days 3, 5, and 7, (N)-MCT and cidofovir treatments at a dose of 100 mg/kg/day caused significant reductions in lung virus titers. Lung virus titers were reduced by about 10-fold in the (N)-MCT-treated mice and by ≥ 1000 -fold in cidofovir-treated animals. Virus in nasal tissue was significantly reduced (about 6-fold) by (N)-MCT treatment on day 5 of the infection. Cidofovir treatment caused ≥ 1000 -fold nasal virus titer reductions on days 3, 5, and 7. Virus in liver, spleen, and kidneys became detectable in placebos starting on day 3. Both (N)-MCT and cidofovir dramatically reduced virus titers in these tissues, and to nearly the same extent. (N)-MCT reduced brain virus titers significantly (by 16-fold) on day 5 of the infection, whereas cidofovir was effective on days 5 and 7, causing virus titer reductions of 630- and 125-fold, respectively. The results demonstrate that (N)-MCT reduced lung, snout, and brain virus titers over multiple days of the infection, but to a lesser extent than cidofovir.

3.4. Effects of delayed treatment on survival from vaccinia virus (IHD strain) infection

Treatments with (N)-MCT and cidofovir by i.p. route were initiated at varying times after infection to determine their impact on survival (Table 3). (N)-MCT at 100 mg/kg/day was significantly effective in preventing mortality when treatment started at 1 and 2 days after virus exposure. Delays in the mean day of death occurred when treatment started as late as 3 days after infection. Treatment with (N)-MCT was also performed using 400 mg/kg/day starting on day 4 of the infection. This treatment had no impact on survival. Cidofovir (100 mg/kg/day) significantly protected mice from death when treatment started as late as 3 days after infection, and delayed the time to death when treatment started at 4 days post-virus exposure.

3.5. Treatment of a vaccinia virus (WR) strain infection in mice

It was previously demonstrated that the vaccinia (WR strain) infection was more difficult to treat with (N)-MCT than was the IHD strain infection in terms of survival benefit (Prichard et

al., 2006; Smee et al., 2007). The i.p. doses tested were 10-100 mg/kg/day. We evaluated (N)-MCT at higher i.p. doses in an attempt to provide a better response to treatment (Table 4). (N)-MCT reduced mortality significantly at 500 mg/kg/day but not at the two lower doses. Mice dying from the infection lived significantly longer than placebos when treated with 250 and 500 mg/kg/day doses of (N)-MCT. Cidofovir at 100 mg/kg/day protected all mice from death. Lung consolidation scores and lung weights were significantly reduced by treatment with both compounds.

Tissue virus titers were determined on day 5 of the vaccinia virus (WR strain) infection (Figure 3). The 500 mg/kg/day dose of (N)-MCT was equal to that of cidofovir in reducing lung virus titers. The other two doses on (N)-MCT also significantly reduced lung virus titers. Differences in activity between cidofovir and (N)-MCT were not statistically significant. Treatment with the compounds markedly reduced liver virus production, and virus titers were also reduced in the spleen. The 500 mg/kg/day dose of (N)-MCT and cidofovir (100 mg/kg/day) reduced brain virus titers significantly.

Discussion

The results indicate that (N)-MCT is effective in treating infections caused by the IHD and WR strains of vaccinia virus in mice using various treatment regimens. The potency of (N)-MCT is less than that of cidofovir, since (N)-MCT required daily treatment for a longer period of time than cidofovir (7 versus 2 days of treatment in this study). However, (N)-MCT appears to be less toxic than cidofovir, at least in mice, based upon our toxicity data, and was well tolerated at the highest dose tested of 1000 mg/kg/day.

The oral activity of (N)-MCT was judged to be similar to that of the i.p. dosing regimen based upon survival benefit. Variability in survival benefit from experiment to experiment was seen at the lower doses. The reason for this is unclear, but may relate to the fact that (N)-MCT is only weakly inhibitory to lung virus titers at the 10 and 30 mg/kg/day doses (Smee et al., 2007). Thus, the factors determining survival and death at these doses in different experiments may be small. For this reason it was important to evaluate oral versus i.p. treatments in the same experiment. Pharmacokinetic studies will need to be conducted to accurately determine oral bioavailability, which to our knowledge have not yet been conducted in any laboratory.

(N)-MCT was less active than cidofovir in its ability to suppress virus titers in the lungs, snout, and brain of mice infected with vaccinia virus. The highest dose of (N)-MCT (500 mg/kg/day) showed an improvement in efficacy over the lower doses. Both (N)-MCT and cidofovir were able to substantially block the spread of virus to the liver and spleen. There was a correlation between high nasal virus titer and elevated titers in the brain. Because cidofovir reduced nasal virus titer more effectively than (N)-MCT, this may have been the reason for the presence of less virus in the brains of cidofovir-treated mice.

Treatment with (N)-MCT could be delayed by 48 hours and still show a beneficial impact on survival. Cidofovir was still beneficial when treatment started as late as 72 h after virus exposure. A high dose of (N)-MCT starting at 4 days was not beneficial, indicating that the window of effective treatment had passed, and the mice could not be rescued by a high dose of compound.

(N)-MCT was effective at 500 mg/kg/day in preventing death in mice infected with the WR strain of vaccinia virus. The compound was reported active at 100 mg/kg/day previously (Prichard et al., 2006; Smee et al., 2007). The WR virus is highly virulent to mice, and antiviral results from different experiments may vary. The effects of (N)-MCT at 500 mg/kg/day were somewhat comparable to those of cidofovir at 100 mg/kg/day. Infections with the IHD strain

of virus have been more consistently treatable with antiviral compounds (Smee et al., 2004, 2007).

It was previously demonstrated in cell culture studies that the potency of (*N*)-MCT was highly dependent on the cell line (Smee et al., 2007). The compound was particularly potent in mouse cells, but much less effective in cells of higher species of animals. Its activity was much lower in human and monkey cells, for example. Work in higher species such as monkeys will be needed to determine the potential utility of treating poxvirus infections in humans with (*N*)-MCT.

Acknowledgements

This work was supported by Contract N01-AI-15435 from the Virology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health. The contents of this article do not necessarily reflect the position or policy of the government and no official endorsement should be inferred. The investigators adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (National Institutes of Health Publication No. 86-23, revised 1985), and used facilities fully accredited by the American Association for Accreditation of Laboratory Animal Care.

References

- Arican O. Topical treatment of molluscum contagiosum with imiquimod 5% cream in Turkish children. *Pediatr. Int* 2006;48:403–405. [PubMed: 16911087]
- Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. *Antiviral Res* 2003;57:13–23. [PubMed: 12615299]
- Baxter KF, Highet AS. Topical cidofovir and cryotherapy - combination treatment for recalcitrant molluscum contagiosum in a patient with HIV infection. *J. Eur. Acad. Dermatol. Venereol* 2004;18:230–231. [PubMed: 15009318]
- Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. *Antiviral Res* 2003;58:101–114. [PubMed: 12742570]
- Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. *J. Infect. Dis* 2000;181:10–19. [PubMed: 10608745]
- Brown J, Janniger CK, Schwartz RA, Silverberg NB. Childhood molluscum contagiosum. *Int. J. Dermatol* 2006;45:93–99. [PubMed: 16445494]
- De Clercq E. Cidofovir in the treatment of poxvirus infections. *Antiviral Res* 2002;55:1–13. [PubMed: 12076747]
- De Clercq E, Neyts J. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. *Rev. Med. Virol* 2004;14:289–300. [PubMed: 15334537]
- Erbağci Z, Erbağci I, Almila Tuncel A. Rapid improvement of human orf (ecthyma contagiosum) with topical imiquimod cream: report of four complicated cases. *J. Dermatolog. Treat* 2005;16:353–356. [PubMed: 16428161]
- Huleihel M, Talishanisky M, Ford H Jr. Marquez VE, Kelley JA, Johns DG, Agbaria R. Dynamics of the antiviral activity of *N*-methanocarbothymidine against herpes simplex virus type 1 in cell culture. *Int. J. Antimicrob. Agents* 2005;25:427–432. [PubMed: 15848299]
- Jahrling PB, Fritz EA, Hensley LE. Countermeasures to the bioterrorist threat of smallpox. *Curr. Mol. Med* 2005;5:817–826. [PubMed: 16375715]
- Magee WC, Hostetler KY, Evans DH. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. *Antimicrob. Agents Chemother* 2005;49:3153–3162. [PubMed: 16048917]
- Marquez VE, Siddiqui MA, Ezzitouni A, Russ P, Wang J, Wagner RW, Matteucci MD. Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? *J. Med. Chem* 1996;39:3739–3747. [PubMed: 8809162]
- Marquez VE, Ben-Kasus T, Barchi JJ Jr. Green KM, Nicklaus MC, Agbaria R. Experimental and structural evidence that herpes 1 kinase and cellular DNA polymerase(s) discriminate on the basis of sugar pucker. *J. Am. Chem. Soc* 2004;126:543–549. [PubMed: 14719951]

- McCabe D, Weston B, Storch G. Treatment of orf poxvirus lesion with cidofovir cream. *Pediatr. Infect. Dis J* 2003;22:1027–1028. [PubMed: 14614378]
- Prichard MN, Keith KA, Quenelle DC, Kern ER. Activity and mechanism of action of *N*-methanocarbothymidine against herpesvirus and orthopoxvirus infections. *Antimicrob. Agents Chemother* 2006;50:1336–1341. [PubMed: 16569849]
- Quenelle DC, Collins DJ, Kern ER. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. *Antimicrob. Agents Chemother* 2003;47:3275–3280. [PubMed: 14506041]
- Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. *Antimicrob. Agents Chemother* 2004;48:404–412. [PubMed: 14742188]
- Russ P, Schelling P, Scapozza L, Folkers G, De Clercq E, Marquez VE. Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbothymine. *J. Med. Chem* 2003;46:5045–5054. [PubMed: 14584954]
- Schelling P, Claus MT, Johner R, Marquez VE, Schulz GE, Scapozza L. Biochemical and structural characterization of (South)-methanocarbothymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cells. *J. Biol. Chem* 2004;279:32832–32838. [PubMed: 15163659]
- Smee DF, Sidwell RW. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. *Antiviral Res* 2003;57:41–52. [PubMed: 12615302]
- Smee DF, Wong MH, Bailey KW, Beadle JR, Hostetler KY, Sidwell RW. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. *Int. J. Antimicrob. Agents* 2004;23:430–437. [PubMed: 15120719]
- Smee DF, Wandersee MK, Bailey KW, Wong M-H, Chu CK, Gadthula S, Sidwell RW. Cell line dependency for antiviral activity and in vivo efficacy of *N*-methanocarbothymidine against orthopoxvirus infections in mice. *Antiviral Res* 2007;73:69–77. [PubMed: 16712967]
- Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holý A, De Clercq E, Niesters HG, Fries E, Maas C, Mulder PG, van der Zeijst BA, Osterhaus AD. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. *Nature* 2006;439:745–748. [PubMed: 16341204]
- Wachsmann M, Petty BG, Cundy KC, Jaffe HS, Fisher PE, Pastelak A, Lietman PS. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. *Antiviral Res* 1996;29:153–161. [PubMed: 8739595]
- Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, De Clercq E, Jones K, Hraby D, Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. *J. Virol* 2005;79:13139–13149. [PubMed: 16189015]
- Zalah L, Huleihel M, Manor E, Konson A, Ford H Jr. Marquez VE, Johns DG, Agbaria R. Metabolic pathways of *N*-methanocarbothymidine, a novel antiviral agent, in native and herpes simplex virus type 1 infected Vero cells. *Antiviral Res* 2002;55:63–75. [PubMed: 12076752]

Figure 1.

Effects of i.p. treatment with (N)-MCT and cidofovir on mean lung consolidation scores and lung weights during a vaccinia virus (IHD strain) respiratory infection in mice. Treatment with (N)-MCT was given twice a day (12 h apart) for 7 days. Treatment with cidofovir was administered once a day for 2 days. Treatment began at 24 hours after virus exposure. There were 5 mice per group. Symbols: open squares - (N)-MCT (100 mg/kg/day); circles - cidofovir (100 mg/kg/day); filled squares - placebo. * $P < 0.05$.

Figure 2.

Effects of i.p. treatment with (N)-MCT and cidofovir on mean tissue virus titers during a vaccinia virus (IHD strain) respiratory infection in mice. Treatment with (N)-MCT was given twice a day (12 h apart) for 7 days. Treatment with cidofovir was administered once a day for 2 days. Treatment began 24 hours after virus exposure. There were 5 mice per group. Symbols: open squares - (N)-MCT (100 mg/kg/day); circles - cidofovir (100 mg/kg/day); filled squares - placebo. * P<0.05.

Figure 3.

Effects of i.p. treatment with (*N*)-MCT and cidofovir on mean tissue virus titers, determined on day 5 of a vaccinia virus (WR strain) respiratory infection in mice. Treatment with (*N*)-MCT was given twice a day (12 h apart) for 7 days. Treatment with cidofovir was administered once a day for 2 days. Treatment began 24 hours after virus exposure. There were 5 mice per group. * $P < 0.05$, ** $P < 0.01$.

Table 1

Effects of i.p. and oral treatment with (N)-MCT on a vaccinia virus (IHD strain) respiratory infection in mice

Compound (mg/kg/day) ^a	Treatment Route	Survivors/Total	MDD ^b
<i>Experiment 1:</i>			
(N)-MCT (100)	i.p.	10/10 ^{***}	-
(N)-MCT (30)	i.p.	9/10 ^{***}	7.0
(N)-MCT (10)	i.p.	3/10 [*]	10.7 ± 3.9 ^{***}
Placebo	i.p.	0/20 ^{***}	6.8 ± 0.5
(N)-MCT (100)	p.o.	10/10 ^{***}	-
(N)-MCT (30)	p.o.	9/10 ^{***}	8.0
(N)-MCT (10)	p.o.	7/10 ^{***}	8.7 ± 1.2 [*]
Placebo	p.o.	0/20	7.1 ± 0.7
<i>Experiment 2:</i>			
(N)-MCT (100)	i.p.	10/10 ^{***}	-
(N)-MCT (30)	i.p.	3/10	8.6 ± 1.6 [*]
(N)-MCT (10)	i.p.	1/10	8.6 ± 1.2 [*]
(N)-MCT (3)	i.p.	3/10	8.9 ± 0.7 ^{**}
Placebo	i.p.	0/10	7.0 ± 0.9 [*]
(N)-MCT (100)	p.o.	7/10 ^{**}	8.3 ± 0.6 [*]
(N)-MCT (30)	p.o.	8/10 ^{***}	7.5 ± 0.7
(N)-MCT (10)	p.o.	0/10	7.8 ± 0.4
(N)-MCT (3)	p.o.	0/10	7.4 ± 0.5
Placebo	p.o.	0/10	7.1 ± 0.6

^aTwice-daily (12 h apart) for 7 days starting 24 hours after virus exposure.^bMean day of death ± SD of mice that died prior to day 21.^{*}
P<0.05^{**}
P<0.01^{***}
P<0.001.

Table 2
Effects of oral treatment with (N)-MCT and i.p. treatment with cidofovir on vaccinia virus (IHD strain) respiratory infections in mice

Compound (mg/kg/day) ^a	Treatment Days	Survivors/Total	MDP ^b	Mean Lung Parameters ± SD (Day 5)		
				Score	Weight (mg)	Virus Titer ^c
(N)-MCT (500)	1-7	10/10 ***	-	0.0 ± 0.0 **	134 ± 11 **	6.7 ± 0.3 **
(N)-MCT (250)	1-7	10/10 ***	-	0.0 ± 0.0 **	122 ± 9 **	6.8 ± 0.4 **
(N)-MCT (100)	1-7	9/10 ***	8.0	0.3 ± 0.3 **	160 ± 29 **	7.5 ± 0.2 **
Cidofovir (100)	1-2	10/10 ***	-	0.0 ± 0.0 **	114 ± 11 **	4.5 ± 0.5 **
Placebo	1-7	0/20	7.0 ± 1.9	1.4 ± 0.2	252 ± 20	8.1 ± 0.3

^aTwice-daily (12 h apart) for (N)-MCT and once-daily for cidofovir, starting 24 h after virus exposure.

^bMean day of death ± SD of mice that died prior to day 21.

^cLog10 PFU/g ± SD.

** P<0.01

*** P<0.001.

Table 3

Effects of delayed i.p. treatment with (N)-MCT and cidofovir on a vaccinia virus (IHD strain) respiratory infection in mice

Compound (mg/kg/day) ^a	Treatment Start Day ^b	Survivors/Total	MDD ^c
(N)-MCT (100)	1	8/10 ***	11.0 ± 1.4 *
Cidofovir (100)	1	10/10 ***	-
Placebo	1	0/10	6.7 ± 0.5
(N)-MCT (100)	2	5/10 *	11.2 ± 1.8 ***
Cidofovir (100)	2	10/10 ***	-
Placebo	2	0/10	6.5 ± 0.5
(N)-MCT (100)	3	2/10	15.5 ± 6.3 *
Cidofovir (100)	3	7/10 **	15.3 ± 4.7 **
Placebo	3	0/10	7.4 ± 0.7
(N)-MCT (100)	4	1/10	7.2 ± 0.7
(N)-MCT (400)	4	0/10	7.0 ± 0.7
Cidofovir (100)	4	3/10	8.9 ± 2.3 *
Placebo	4	0/10	6.9 ± 0.7

^aTwice-daily (12 h apart) for 7 days with (N)-MCT and once-daily for 2 days with cidofovir.

^bAfter virus exposure.

^cMean day of death ± SD of mice that died prior to day 21.

* P<0.05

** P<0.01

*** P<0.001.

Effects of i.p. treatment with (N)-MCT and cidofovir on survival and lung infection parameters during a vaccinia virus (WR strain) respiratory infection in mice

Compound (mg/kg/day) ^a	Treatment Days	Survivors/Total	MDD ^b	Mean Lung Parameters ± SD (Day 5)	
				Score	Weight (mg)
(N)-MCT (500)	1-7	8/10 ***	11.5 ± 2.1 **	0.0 ± 0.0 **	140 ± 25 **
(N)-MCT (250)	1-7	2/10	9.4 ± 2.2 ***	0.1 ± 0.2 *	162 ± 16 **
(N)-MCT (100)	1-7	2/10	6.3 ± 2.4	0.2 ± 0.3 *	156 ± 38 *
Cidofovir (100)	1-2	10/10 ***	-	0.2 ± 0.3 *	134 ± 11 **
Placebo	1-7	0/20	7.0 ± 0.5	0.7 ± 0.3	216 ± 21

^aTwice-daily (12 h apart) for (N)-MCT and once-daily for cidofovir, starting 24 hours after virus exposure.

^bMean day of death ± SD of mice that died prior to day 21.

* P<0.05

** P<0.01

*** P<0.001.